{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:40:59Z","timestamp":1791492059674,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013826","name":"Candys Foundation","doi-asserted-by":"publisher","award":["2017-218"],"award-info":[{"award-number":["2017-218"]}],"id":[{"id":"10.13039\/501100013826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Hospital of Copenhagen\u2014Rigshospitalet"},{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","award":["OCAY-18-774-OFIL"],"award-info":[{"award-number":["OCAY-18-774-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adipose-derived mesenchymal stem\/stromal cells (ASCs) are proposed as a new xerostomia treatment. The study evaluated the long-term safety and effectiveness of allogeneic ASCs in radiation-induced xerostomia among patients with previous oropharyngeal cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study constitutes 3-year follow-up on the original 10 patients who received allogeneic ASCs injections to the submandibular and parotid glands as part of the MESRIX-II trial. The MESRIX-II trial included the preliminary 4-month follow-up. The primary endpoint was long-term safety. Secondary endpoints were effectiveness evaluated by changes in salivary flow rate and patient-reported outcomes (PROs). Immune response was evaluated by assessing the development of donor-specific antibodies (DSA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>All 10 MESRIX-II patients completed the long-term follow-up (ie, no missing data). During the long-term follow-up, 2 patients encountered a significant adverse event, which was determined to be unrelated to the treatment. No DSAs were detectable at 3 years. The stimulated salivary flow rate increased significantly from an average of 0.66 mL\/minute at baseline to 0.86 mL\/minute at follow-up, corresponding to an increase of 0.20 [95% CI 0.08 to 0.30] mL\/minute, or approximately 30%. Among the PROs, sticky saliva symptoms were reduced, with a \u221220.0 [95% CI \u221237.3 to \u22122.7] units.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>In conclusion, this study is the first to present long-term follow-up outcomes of allogeneic ASC treatment as a therapeutic option for radiation-induced xerostomia. The study found that ASC treatment appears safe, and there were no indications of adverse immune responses at the 3-year follow-up. Further studies are warranted to evaluate the findings in larger settings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/stcltm\/szae017","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T16:32:44Z","timestamp":1712334764000},"page":"515-521","source":"Crossref","is-referenced-by-count":10,"title":["Long-Term Outcome Following Treatment With Allogeneic Mesenchymal Stem\/Stromal Cells for Radiation-Induced Hyposalivation and Xerostomia"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0336-5411","authenticated-orcid":false,"given":"Kathrine Kronberg","family":"Jakobsen","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet\u2014Copenhagen University Hospital , Copenhagen , Denmark"},{"name":"Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1637-2146","authenticated-orcid":false,"given":"Charlotte Duch","family":"Lynggaard","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet\u2014Copenhagen University Hospital , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja","family":"Paaske","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet\u2014Copenhagen University Hospital , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda-Louise Fenger","family":"Carlander","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet\u2014Copenhagen University Hospital , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3668-5393","authenticated-orcid":false,"given":"Jens","family":"Kastrup","sequence":"additional","affiliation":[{"name":"Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Werner","family":"Hauge","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Rigshospitalet , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[{"name":"Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital , Copenhagen , Denmark"},{"name":"Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gr\u00f8nh\u00f8j","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet\u2014Copenhagen University Hospital , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian von","family":"Buchwald","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet\u2014Copenhagen University Hospital , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"2024061106303069400_CIT0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume-title":"CA Cancer J Clin","author":"Sung","year":"2021"},{"issue":"e20200854","key":"2024061106303069400_CIT0002","first-page":"1","article-title":"Prevalence of hyposalivation and associated factors in survivors of head and neck cancer treated with radiotherapy","volume":"29","author":"Schulz","year":"2021","journal-title":"J Appl Oral Sci"},{"key":"2024061106303069400_CIT0003","first-page":"487","article-title":"Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer","volume-title":"Acta Oncol","author":"Jensen","year":"1994"},{"key":"2024061106303069400_CIT0004","first-page":"91","article-title":"Quality of life in survivors of oropharyngeal cancer: a systematic review and meta-analysis of 1366 patients","volume-title":"Eur J Cancer","author":"H\u00f8xbroe Michaelsen","year":"2017"},{"key":"2024061106303069400_CIT0005","first-page":"213","article-title":"Prevention and treatment of the consequences of head and neck radiotherapy","volume-title":"Crit Rev Oral Biol Med","author":"Vissink","year":"2003"},{"key":"2024061106303069400_CIT0006","first-page":"1061","article-title":"A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact","volume-title":"Support Care Cancer","author":"Jensen","year":"2010"},{"key":"2024061106303069400_CIT0007","first-page":"335","article-title":"Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies","volume-title":"Oral Surg Oral Med Oral Pathol Oral Radiol","author":"Jensen","year":"2014"},{"issue":"1","key":"2024061106303069400_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-017-1856-0","article-title":"First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial","volume":"18","author":"Gr\u00f8nh\u00f8j","year":"2017","journal-title":"Trials"},{"key":"2024061106303069400_CIT0009","first-page":"581","article-title":"Safety and efficacy of mesenchymal stem cells for radiation-induced xerostomia: a randomized, placebo-controlled phase 1\/2 trial (MESRIX)","volume-title":"Int J Radiat Oncol Biol Phys","author":"Gr\u00f8nh\u00f8j","year":"2018"},{"key":"2024061106303069400_CIT0010","first-page":"2890","article-title":"Long-term safety of treatment with autologous mesenchymal stem cells in patients with radiation-induced xerostomia: primary results of the MESRIX phase I\/II randomized trial","volume-title":"Clin Cancer Res","author":"Lynggaard","year":"2022"},{"key":"2024061106303069400_CIT0011","first-page":"478","article-title":"Intraglandular off-the-shelf allogeneic mesenchymal stem cell treatment in patients with radiation-induced xerostomia: a safety study (MESRIX-II)","volume-title":"Stem Cells Transl Med","author":"Lynggaard","year":"2022"},{"key":"2024061106303069400_CIT0012","first-page":"4664917","article-title":"GMP compliant production of a cryopreserved adipose-derived stromal cell product for feasible and allogeneic clinical use","volume-title":"Stem Cells Int","author":"Haack-S\u00f8rensen","year":"2022"},{"key":"2024061106303069400_CIT0013","first-page":"1963","article-title":"Cryopreserved off-the-shelf allogeneic adipose-derived stromal cells for therapy in patients with ischemic heart disease and heart failure\u2014a safety study","volume-title":"Stem Cells Transl Med","author":"Kastrup","year":"2017"},{"key":"2024061106303069400_CIT0014","first-page":"5680","article-title":"The importance of HLA assessment in \u201coff-the-shelf\u201d allogeneic mesenchymal stem cells based-therapies","volume-title":"Int J Mol Sci","author":"Kot","year":"2019"},{"key":"2024061106303069400_CIT0015","first-page":"8421281","article-title":"Safety and feasibility of repeated intrathecal allogeneic bone marrow-derived mesenchymal stromal cells in patients with neurological diseases","volume-title":"Stem Cells Int","author":"Pan","year":"2019"},{"key":"2024061106303069400_CIT0016","first-page":"215","article-title":"Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a Controlled Randomized Phase I\/II Trial","volume-title":"Stem Cells Transl Med","author":"Matas","year":"2019"},{"key":"2024061106303069400_CIT0017","first-page":"639315","article-title":"Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis","volume-title":"Front Neurol","author":"Petrou","year":"2021"},{"key":"2024061106303069400_CIT0018","first-page":"106736","article-title":"Clinical benefits of single vs repeated courses of mesenchymal stem cell therapy in epilepsy patients","volume-title":"Clin Neurol Neurosurg","author":"Hlebokazov","year":"2021"},{"key":"2024061106303069400_CIT0019","first-page":"110306","article-title":"Repeated intra-articular administration of equine allogeneic peripheral blood-derived mesenchymal stem cells does not induce a cellular and humoral immune response in horses","volume-title":"Vet Immunol Immunopathol","author":"Van Hecke","year":"2021"},{"key":"2024061106303069400_CIT0020","first-page":"162","article-title":"A review of saliva: normal composition, flow, and function","volume-title":"J Prosthet Dent","author":"Humphrey","year":"2001"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/13\/6\/515\/58183273\/szae017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/13\/6\/515\/58183273\/szae017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:52:15Z","timestamp":1718135535000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/13\/6\/515\/7641461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,10]]},"published-print":{"date-parts":[[2024,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szae017","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,6,1]]}}}